Committed to a Brighter Outlook
According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fueled our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future. Our efforts have yielded our currently marketed antibacterial, XERAVA™ (eravacycline) for injection, as well as several promising investigational compounds that are currently available for out-licensing.
Please contact us to learn more.